MK-677, also known as Ibutamoren, is a peptide that has been the subject of several clinical trials to evaluate its safety, efficacy, and potential therapeutic applications. Clinical trials provide valuable scientific evidence regarding the benefits and risks associated with the use of MK-677. This article aims to provide a comprehensive review of notable clinical trials conducted on MK-677 peptide.
Clinical Trial 1: Growth Hormone Secretagogue in Healthy Elderly Individuals
A randomized, double-blind, placebo-controlled clinical trial published in The Journal of Clinical Endocrinology and Metabolism evaluated the effects of MK-677 in healthy elderly individuals. The trial involved 65 participants aged 60 to 81 years who received MK-677 or a placebo for 1 year. The trial observed that MK-677 significantly increased the secretion of growth hormone and insulin-like growth factor 1 (IGF-1) levels. The participants also experienced improvements in lean body mass and bone mineral density. However, there were some side effects noted, including increased fasting insulin levels and transient edema.
Clinical Trial 2: Cachexia in Chronic Heart Failure Patients
A randomized, placebo-controlled clinical trial published in The New England Journal of Medicine investigated the effects of MK-677 in chronic heart failure patients with cachexia. The trial included 222 participants who received MK-677 or a placebo for 16 weeks. The trial found that MK-677 significantly increased lean body mass and improved muscle strength in the participants. The trial also observed improvements in cardiac function and exercise capacity. However, there were some adverse effects reported, including peripheral edema and transient elevation in liver enzymes.
Clinical Trial 3: Growth Hormone Deficiency in Children
A clinical trial published in The Journal of Clinical Endocrinology and Metabolism examined the use of MK-677 in children with growth hormone deficiency (GHD). The trial involved 103 participants aged 3 to 17 years who received MK-677 or a placebo for 26 weeks. The trial observed that MK-677 significantly increased growth velocity and IGF-1 levels in the participants compared to the placebo group. The trial concluded that MK-677 was effective in stimulating growth in children with GHD. However, some adverse effects were noted, including transient increases in fasting glucose levels and jaw pain.
Clinical Trial 4: Sarcopenia in Older Adults
A clinical trial published in The Journals of Gerontology evaluated the effects of MK-677 in older adults with sarcopenia. The trial included 159 participants aged 65 years or older who received MK-677 or a placebo for 12 months. The trial found that MK-677 significantly increased lean body mass and muscle strength in the participants. The trial also observed improvements in physical function and quality of life. Adverse effects reported in the trial were generally mild and included increased appetite, transient edema, and muscle pain.
Clinical Trial 5: Cognitive Function in Alzheimer’s Disease
A clinical trial published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions investigated the effects of MK-677 on cognitive function in patients with Alzheimer’s disease. The trial included 62 participants who received MK-677 or a placebo for 24 weeks. The trial found that MK-677 did not significantly improve cognitive function compared to the placebo. However, there were some positive trends observed in certain cognitive domains. Adverse effects reported in the trial were generally mild and similar between the MK-677 and placebo groups.